1,085,398 Shares in CytomX Therapeutics, Inc. $CTMX Purchased by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP purchased a new position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,085,398 shares of the biotechnology company’s stock, valued at approximately $4,070,243. CytomX Therapeutics makes up 0.0% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 28th biggest position. Seven Fleet Capital Management LP owned approximately 0.50% of CytomX Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of CTMX. Bank of America Corp DE acquired a new position in CytomX Therapeutics in the second quarter worth $56,560,000. Freestone Grove Partners LP bought a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at $71,000. Jupiter Topco LLC purchased a new stake in shares of CytomX Therapeutics in the second quarter worth about $175,000. Elmind Capital LP bought a new stake in shares of CytomX Therapeutics during the second quarter valued at approximately $17,062,500. Finally, AWM Investment Company Inc. purchased a new position in shares of CytomX Therapeutics in the second quarter valued at about $562,000. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Stock Performance

NASDAQ CTMX traded down $0.21 during trading hours on Friday, hitting $3.21. 2,172,091 shares of the company traded hands, compared to its average volume of 4,851,368. The business’s 50-day moving average is $3.45 and its 200-day moving average is $4.04. CytomX Therapeutics, Inc. has a twelve month low of $1.90 and a twelve month high of $8.21. The stock has a market capitalization of $699.46 million, a price-to-earnings ratio of -6.42 and a beta of 2.12.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). CytomX Therapeutics had a negative net margin of 435.21% and a negative return on equity of 38.46%. The company had revenue of $1.42 million for the quarter, compared to the consensus estimate of $12.39 million. Analysts predict that CytomX Therapeutics, Inc. will post -0.4 EPS for the current year.

Analysts Set New Price Targets

CTMX has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CytomX Therapeutics in a research note on Tuesday, June 16th. Zacks Research cut CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. HC Wainwright reduced their price target on CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. JPMorgan Chase & Co. dropped their price target on CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating for the company in a research note on Thursday, August 13th. Finally, Wolfe Research began coverage on CytomX Therapeutics in a research note on Tuesday, May 19th. They set an “outperform” rating and a $6.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, CytomX Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.90.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.